Abstract
Mpox outbreaks in Central Africa have been declared a public health emergency of international concern by the World Health Organization. Fortunately, real-world effectiveness studies of the MVA-BN vaccine indicate that it has an effectiveness of 74% after one dose, and 82% after two doses against mpox. However, given the very limited supply of vaccines in Central Africa, there remain questions around the optimal deployment of limited MVA-BN doses. In this study, we consider whether more mpox cases might be averted by following the traditional two-dose vaccine regimen (4 week dosing interval), or by giving a single dose of MVA-BN to as many individuals as possible. We find that the optimal strategy depends on both, (i) the degree to which a subpopulation might be at higher risk of mpox, or severe mpox, infections, and (ii) how long ago the first dose was administered to the most at-risk subpopulation.
Competing Interest Statement
CRM is a member of the WHO SAGE advisory group on smallpox and mpox and was a member of the advisory board for Bavarian Nordic in 2022. DSK has collaborated with employees from Merck KGaG, Merck Co., GSK and Zydus Cadila to provide data analysis relating to therapeutic products being developed for treatment of malaria. The authors have no other conflicts of interest to declare.
Funding Statement
This work is supported by National Health and Medical Research Council of Australia Investigator Grants (GNT2016907 to CRM, GNT1173528 to DC, GNT1173027 to MPD). DSK is supported by a University of New South Wales Scientia Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study provides modelling and data analysis of the results from a previously published systematic review and meta-analysis of human data. The original systematic review and meta-analysis is located at, Berry et al. Nature Communications 15:3856 (2024)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used for analysis and modelling in this present study are available in the original systematic review and meta-analysis reported in Berry et al., Nature Communications 15:3856 (2024) and the accompanying GitHub page
https://github.com/iap-sydney/Mpox_ELISA_Effectiveness_correlates
